These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27193993)

  • 1. Deferasirox AUC efficacy cutoff and role of pharmacogenetics.
    Allegra S; Cusato J; De Francia S; Massano D; Piga A; D'Avolio A
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1155-7. PubMed ID: 27193993
    [No Abstract]   [Full Text] [Related]  

  • 2. Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
    Allegra S; De Francia S; Longo F; Massano D; Cusato J; Arduino A; Pirro E; Piga A; D'Avolio A
    Biomed Pharmacother; 2016 Dec; 84():1510-1512. PubMed ID: 27881236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
    Allegra S; Cusato J; De Francia S; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2017 May; 69(5):525-528. PubMed ID: 27230486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of iron overload and chelation with deferasirox.
    Choudhry VP; Naithani R
    Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.
    Allegra S; De Francia S; Cusato J; Arduino A; Massano D; Longo F; Piga A; D'Avolio A
    Pharmacogenomics; 2017 Apr; 18(6):539-554. PubMed ID: 28346059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
    Allegra S; De Francia S; Cusato J; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2016 Nov; 68(11):1417-1421. PubMed ID: 27672004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
    Lu MY; Wang N; Wu WH; Lai CW; Kuo PH; Chiang PH; Lin KH; Wu TH
    Clin Ther; 2015 Aug; 37(8):1751-60. PubMed ID: 26093827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do we need more iron-chelating drugs?
    Kontoghiorghes GJ
    Lancet; 2003 Aug; 362(9382):495-6. PubMed ID: 12927446
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of pharmacogenetics on deferasirox AUC and efficacy.
    Cusato J; Allegra S; De Francia S; Massano D; Piga A; D'Avolio A
    Pharmacogenomics; 2016 Apr; 17(6):561-72. PubMed ID: 27043265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major.
    Lu MY; Lin TH; Chiang PH; Kuo PH; Wang N; Wu WH; Lin KH; Wu TH
    Ther Drug Monit; 2017 Apr; 39(2):185-191. PubMed ID: 28141745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.
    Voskaridou E; Plata E; Douskou M; Papadakis M; Delaki EE; Christoulas D; Terpos E
    Br J Haematol; 2010 Jan; 148(2):332-4. PubMed ID: 19863539
    [No Abstract]   [Full Text] [Related]  

  • 13. Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®).
    Vini D; Servos P; Drosou M
    Eur J Haematol; 2011 Mar; 86(3):274-5. PubMed ID: 21198860
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.
    Galanello R; Piga A; Alberti D; Rouan MC; Bigler H; Séchaud R
    J Clin Pharmacol; 2003 Jun; 43(6):565-72. PubMed ID: 12817519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major.
    Davies GI; Davies D; Charles S; Barnes SL; Bowden D
    Pediatr Allergy Immunol; 2017 Mar; 28(2):199-201. PubMed ID: 27797415
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.
    Ford JM; Rojkjaer L
    Haematologica; 2008 Jun; 93(6):e49; discussion e50. PubMed ID: 18515872
    [No Abstract]   [Full Text] [Related]  

  • 17. Deferasirox: pharmacokinetics and clinical experience.
    Galanello R; Campus S; Origa R
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
    Unal S; Hazirolan T; Eldem G; Gumruk F
    Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICL670A: preclinical profile.
    Nick H; Wong A; Acklin P; Faller B; Jin Y; Lattmann R; Sergejew T; Hauffe S; Thomas H; Schnebli HP
    Adv Exp Med Biol; 2002; 509():185-203. PubMed ID: 12572995
    [No Abstract]   [Full Text] [Related]  

  • 20. Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
    Mattioli F; Puntoni M; Marini V; Fucile C; Milano G; Robbiano L; Perrotta S; Pinto V; Martelli A; Forni GL
    Eur J Haematol; 2015 Apr; 94(4):310-7. PubMed ID: 25081908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.